You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Interdisciplinary Approaches to Deal with Alzheimer’s Disease
Edit
This entry is adapted from the peer-reviewed paper 10.3390/biomedicines10112922

Alzheimer’s disease is one of the most common neurodegenerative diseases in the western population. The incidence of this disease increases with age. Rising life expectancy and the resulting increase in the ratio of elderly in the population are likely to exacerbate socioeconomic problems. Alzheimer’s disease is a multifactorial disease. In addition to amyloidogenic processing leading to plaques, and tau pathology, but also other molecular causes such as oxidative stress or inflammation play a crucial role. Unfortunately, all previous single-domain interventions have been shown to have limited benefit to patients. However, the latest studies indicate that combining these efforts into multidomain approaches may have increased preventive or therapeutic potential.

Alzheimer’s disease nutritional approaches physical activity socioeconomic factors cognition-oriented treatment communication oral health interdisciplinary approaches multimodal intervention multidomain intervention

1. Introduction

Alzheimer’s disease (AD) is the most prevalent form of dementia and is characterized by behavioral and cognitive impairments. It results in a loss of memory and acquired skills, as well as a decrease in participation in daily activities, communication skills, social interactions and quality of life leading to an increasing burden on caregivers [1][2]. The main histopathological hallmarks of AD are the severe accumulation of amyloid-β in extracellular neuritic plaques as well as intracellular neurofibrillary tangles (NFTs) in vulnerable brain regions such as the hippocampus and cortex [3]. Based on the onset of symptoms and pathological changes in the cortex and hippocampus, clinical AD stages can be classified into at least four phases. The pre-symptomatic/pre-clinical stage is asymptomatic despite early pathological changes in the cortex and hippocampal formation [4][5][6], followed by mild cognitive impairment (MCI). MCI shows limitations in some cognitive domains on functional examination without restrictions in the ability to cope with everyday life [7][8][9] but definite laboratory evidence, including biomarkers such as low amyloid-β and increased tau proteins in the cerebrospinal fluid [5]. Mild/early dementia due to AD is characterized by symptoms such as spatial and temporal disorientation, loss of memory and concentration, word-finding difficulties, and the development of depression. In the moderate stage of AD, increased memory loss, impairment of visuospatial abilities leading to difficulties in recognizing family members and friends, and problems with language and communication occur [5][6][10]. The final stage of AD, severe/late AD, is associated with severe accumulation of NTFs and senile plaques in the entire cortex area, resulting in advanced functional and cognitive impairment, incontinence, dysphagia, and complete dependence on caregivers [5].
Currently (2020), AD is estimated to affect 55 million people worldwide. Global AD prevalence is predicted to increase to 139 million people living with AD by 2050 due to the aging population, making AD a major public health concern. Yet, to date, there are only two classes of approved drugs to treat persons with Alzheimer’s disease (PwAD): Cholinesterase enzyme inhibitors and N-methyl-D-aspartate (NMDA) inhibitors. Acetylcholine-producing cells are destroyed in AD by different physiological processes. Treatment with acetylcholinesterase inhibitors such as donepezil, galantamine and rivastigmine blocks the catabolism of acetylcholine, increasing acetylcholine concentration in the synaptic cleft and thus cholinergic transmission in the brain [5][11][12][13]. Overactivation of NMDA-receptors leads to increased intracellular calcium levels, promoting cell death and synaptic dysfunction. The use of partial NMDA antagonists such as memantine, which can be taken in combination with cholinesterase inhibitors, prevents NMDA-receptor overactivation and restores its normal activity [14][15]. However, these medications are only temporary effective in treating the symptoms of AD by improving quality of life but do not cure or prevent the disease.
Most AD cases occur sporadically (known as sporadic Alzheimer’s disease, SAD) with the age of onset above 65 years. Less than 10% of AD cases are caused by genetic familial mutations leading to earlier disease onset, usually between the age of 30 and 60 (known as early onset Alzheimer’s disease, EOAD or familial Alzheimer’s disease, FAD). AD is considered a multifactorial disease as it is characterized by impairments in multiple cellular processes. In addition to cholinergic dysfunction and the well-known Abeta (Aβ) and Tau pathology of AD, inflammation, oxidative stress, as well as, e.g., alterations in lipid and energy metabolism are also involved in the pathogenesis of AD.
The Lancet Commission on dementia prevention, intervention and care [16] recently identified 12 potentially modifiable risk factors for dementia that account for around 40% of dementia cases worldwide. These include, among others, physical inactivity, low social contact, obesity, and associated diabetes. Frequent physical activity, promotion of communication to maintain social interactions, and a healthy diet to avoid the risks of obesity and diabetes may therefore affect neuropathological damage and cognitive reserve [16] and contribute to the prevention or delay of dementia. According to current literature, the intraoral condition could also represent such a modifiable risk factor [17][18][19].
Reducing modifiable risk factors, in addition to pharmacological interventions, is an important approach in dementia treatment. According to Spector and Orrell’s biopsychosocial (BPS) model [20], dementia is a multifactorial disease in which psychosocial and biological processes are interrelated. Both domains include fixed, non-modifiable factors (e.g., age; education) and tractable, modifiable factors (e.g., physical health; social interaction, mental stimulation). Treatment plans should be tailored to the individual’s needs. Factors amenable to change are identified with the aim of influencing them through medical and non-pharmacological interventions [20][21]. In recent years, non-pharmacological interventions have become increasingly important in the management of dementia and in the effort to improve living with dementia and maintain quality of life [1][7][22][23][24]. Non-pharmacological interventions include evidence-based psychological, bodily, nutritional, digital or basic methods and approaches, that are individually selected and adjusted to the persons’ needs in their courses of disease [7][24]. Among these, cognition-oriented treatments (COT) [1][24][25], physical activity [26], and diet [27] form an integral part.

2. Feasible Options

A large-scale meta-analysis and systematic review of more than 150 RCTs and more than 240 observational prospective studies identified evidence-based modifiable factors for the prevention of AD [28]. The Lancet Commission also recommends addressing risk factors that favor the development of dementia across the lifespan, as this can affect cognitive reserve and delay neuropathological developments [16][29]. For example, a reduction in oxidative stress or effects on mitochondria, in general, are known to be involved in physical activity and nutrition [30]. In this context, the effect of PGC-1α, a mitochondrial super-regulator, has been reported to be affected by AD and might be an interesting target for further studies [31]. Moreover, dietary interventions influence cellular energy metabolism and can therefore have an impact on synaptic plasticity [29], a parameter, which highly correlates with cognitive reserve and cognitive activity in general. Synaptic plasticity is further influenced by different lipids [32]. E.g., plasmalogens or phosphatidyl-choline in combination with choline/UMP-choline or DHA have been shown or are at least discussed to increase several synaptic markers such as synaptophysin or PSD95 [33][34]. There is growing evidence that combined dietary components show synergistic beneficial effects on AD pathology  [35][36]. In general, interventions in the prodromal and early stages of AD may correct the deficiency of key nutritional elements that could otherwise lead to the loss of synapses and neurons [36].

Up to now, addressing only one risk factors or molecular mechanism has been proven to be not sufficient to deal with AD, making a multidisciplinary approach even more attractive. Therefore, multidomain interventions that target preventive, or early-stage disease show potential for delaying the onset of dementia [29][37][38][39][40][41][42], even with existing structural changes in the brain [43][44][45]. Physical activity and cognitive activities stimulate cerebral blood flow and the production of neurotrophic factors that influence hippocampal neuroplasticity  [29][42][44]. Also, physical activity and dietary interventions are known to address similar mechanisms involved in AD. Dietary modifications combined with aerobic physical activity led to cognitive improvements in participants with elevated blood pressure [46].  Since high blood pressure is also a risk factor for the onset and progression of AD, combined nutritional approaches with specific physical activity are promising for AD. These are only a few examples that combine different approaches to adjust the dysregulated metabolic homeostasis in AD synergistically from different angles, resulting in an elevated beneficial potential with respect to AD compared to approaches based on a single intervention.

To improve cognition, multidomain interventions should comprise at least three modalities, one of which is a cognitive approach [29]. Up to now, cognition and physical training is the most common combination of the multidomain approaches [29][41][42][47]. Communication-based interventions and outcomes have rarely been considered in COT and in multidomain approaches so far, despite the fact that impaired communication can form a major burden in disease progression [48][49], and beneficial effects of COT are partly attributed to language activities and communicative interaction [50][51]. More recently, a person-centered approach with individually determined goals has become prevalent in speech and language therapy  [52][53][54]. Similarly, multidomain interventions with individualized contents achieve the greatest effect sizes [29]. In many studies, cognition is the primary outcome used to test the effectiveness of the intervention. Unfortunately, most of the chosen assessments or outcomes have little relation to the demands of daily living [29][55], but rather measure higher cognitive functions [308]. Future work should therefore consider communication skills as an outcome measure. Corresponding parameters would be, for example, the proportion of topic-related utterances and empty utterances or the global coherence in the discourse of people with dementia  [56][57].

Nutritional interventions and educational support play an important role in supporting and counseling PwAD and their families throughout the course of the disease [38][58][59][60]. The success of psychoeducational interventions depends on clear communication of theoretical contents and the active involvement of carers in practice sequences to implement new skills [49][58].

Although there is a growing interest in interrelated biochemical processes in intraoral inflammation and the occurrence and progression of AD [61][62], there are few clinical studies investigating the effectiveness of oral treatment approaches in AD. Support of oral hygiene and health, prevention and diagnosis of periodontal disease are promising approaches in dementia care that have not yet been addressed in multidomain interventions but should receive more attention in the future  [66][67][68][69]. Difficulties in recruitment include ethical issues, the health status of people with disabilities, lack of compliance, required involvement of relatives, treatment limitations, and economic issues [63][64][65]. However, oral treatment approaches are very promising to be integrated into a multidomain approach. In particular, approaches to nutrition, oral hygiene, mobility and masticatory function can be optimally coordinated and adapted to individual needs, which overall contributes to an improvement in the quality of life of PwAD. Sessions can take place in groups as well as individually and thus promote social activities, as is also recommended in this context [16]. In this context, diabetes mellitus, recently identified as an additional risk factor for the development of AD  [70], should also be mentioned, even though the underlying mechanisms have not yet been clarified  [71]. It is known that there is a bidirectional relationship between the presence of intraoral inflammation, especially periodontitis, and diabetes mellitus  [72]. Thus, an improvement of the intraoral condition also fulfills the previously formulated need to implement a diabetes mellitus-protective lifestyle for AD prevention [28].

Taken together, treatments based on multicomponent or even multidisciplinary approaches revealed more pronounced benefits than single interventions. Therefore, we suggest a tight interlink between different treatment strategies resulting in an interdisciplinary approach, covering in particular nutritional counseling, supervised physical training, oral health, and cognitive-oriented communication intervention to maintain quality of life in AD. Although the reviewed literature is promising, further studies addressing these interdisciplinary aims are needed to prove effectiveness.

References

  1. Clare, L.; Teale, J.C.; Toms, G.; Kudlicka, A.; Evans, I.; Abrahams, S.; Goldstein, L.H.; Hindle, J.V.; Ho, A.K.; Jahanshahi, M.; et al. Cognitive rehabilitation, self-management, psychotherapeutic and caregiver support interventions in progressive neurodegenerative conditions: A scoping review. NeuroRehabilitation 2018, 43, 443–471.
  2. Kudlicka, A.; Martyr, A.; Bahar-Fuchs, A.; Woods, B.; Clare, L. Cognitive rehabilitation for people with mild to moderate dementia. Cochrane Database Syst. Rev. 2019, 28, 707.
  3. Selkoe, D.J. Cell biology of protein misfolding: The examples of Alzheimer’s and parkinson’s diseases. Nat. Cell Biol. 2004, 6, 1054–1061.
  4. Dubois, B.; Hampel, H.; Feldman, H.H.; Scheltens, P.; Aisen, P.; Andrieu, S.; Bakardjian, H.; Benali, H.; Bertram, L.; Blennow, K.; et al. Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimer’s Dement. 2016, 12, 292–323.
  5. Kumar, A.; Sidhu, J.; Goyal, A.; Tsao, J.W. Alzheimer disease. In Statpearls; StatPearls Publishing: Treasure Island, FL, USA, 2022.
  6. Breijyeh, Z.; Karaman, R. Comprehensive review on Alzheimer’s disease: Causes and treatment. Molecules 2020, 25, 5789.
  7. Bahar-Fuchs, A.; Martyr, A.; Goh, A.M.; Sabates, J.; Clare, L. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst. Rev. 2019, 3, CD013069.
  8. Wu, J.; Ma, Y.; Ren, Z. Rehabilitative effects of virtual reality technology for mild cognitive impairment: A systematic review with meta-analysis. Front. Psychol. 2020, 11, 1811.
  9. Mueller, K.D.; Hermann, B.; Mecollari, J.; Turkstra, L.S. Connected speech and language in mild cognitive impairment and Alzheimer’s disease: A review of picture description tasks. J. Clin. Exp. Neuropsychol. 2018, 40, 917–939.
  10. Wattmo, C.; Minthon, L.; Wallin, A.K. Mild versus moderate stages of Alzheimer’s disease: Three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy. Alzheimer’s. Res. 2016, 8, 7.
  11. Eldufani, J.; Blaise, G. The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: A review of recent clinical applications. Alzheimer’s Dement. 2019, 5, 175–183.
  12. Singh, R.; Sadiq, N.M. Cholinesterase inhibitors. In Statpearls; StatPearls Publishing: Treasure Island, FL, USA, 2022.
  13. Chen, J.H. Microscopic features for the identification of chinese drugs in ranunculaceus. Zhong Yao Tong Bao 1985, 10, 15–17.
  14. Khoury, R.; Grysman, N.; Gold, J.; Patel, K.; Grossberg, G.T. The role of 5 ht6-receptor antagonists in Alzheimer’s disease: An update. Expert Opin. Investig. Drugs 2018, 27, 523–533.
  15. Wang, R.; Reddy, P.H. Role of glutamate and nmda receptors in Alzheimer’s disease. J. Alzheimer’s Dis. 2017, 57, 1041–1048.
  16. Livingston, G.; Huntley, J.; Sommerlad, A.; Ames, D.; Ballard, C.; Banerjee, S.; Brayne, C.; Burns, A.; Cohen-Mansfield, J.; Cooper, C.; et al. Dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet 2020, 396, 413–446.
  17. Dioguardi, M.; Crincoli, V.; Laino, L.; Alovisi, M.; Sovereto, D.; Mastrangelo, F.; Lo Russo, L.; Lo Muzio, L. The role of periodontitis and periodontal bacteria in the onset and progression of Alzheimer’s disease: A systematic review. J. Clin. Med. 2020, 9, 495.
  18. Kaliamoorthy, S.; Nagarajan, M.; Sethuraman, V.; Jayavel, K.; Lakshmanan, V.; Palla, S. Association of Alzheimer’s disease and periodontitis—A systematic review and meta-analysis of evidence from observational studies. Med. Pharm. Rep. 2022, 95, 144–151.
  19. Parra-Torres, V.; Melgar-Rodríguez, S.; Muñoz-Manríquez, C.; Sanhueza, B.; Cafferata, E.A.; Paula-Lima, A.C.; Díaz-Zúñiga, J. Periodontal bacteria in the brain-implication for Alzheimer’s disease: A systematic review. Oral Dis. 2021.
  20. Spector, A.; Orrell, M. Using a biopsychosocial model of dementia as a tool to guide clinical practice. Int. Psychogeriatr. 2010, 22, 957–965.
  21. Revolta, C.; Orrell, M.; Spector, A. The biopsychosocial (bps) model of dementia as a tool for clinical practice. A pilot study. Int. Psychogeriatr. 2016, 28, 1079–1089.
  22. Clare, L.; Linden, D.E.J.; Woods, R.T.; Whitaker, R.; Evans, S.J.; Parkinson, C.H.; van Paasschen, J.; Nelis, S.M.; Hoare, Z.; Yuen, K.S.L.; et al. Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: A single-blind randomized controlled trial of clinical efficacy. Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry 2010, 18, 928–939.
  23. Clare, L.; Kudlicka, A.; Oyebode, J.R.; Jones, R.W.; Bayer, A.; Leroi, I.; Kopelman, M.; James, I.A.; Culverwell, A.; Pool, J.; et al. Goal-oriented cognitive rehabilitation for early-stage Alzheimer’s and related dementias: The great rct. Health Technol. Assess. 2019, 23, 1–242.
  24. Ninot, G. Psychosocial interventions and dementia. Pract. Guide Fond. Médéric Alzheimer 2021, 1–100.
  25. Gavelin, H.M.; Lampit, A.; Hallock, H.; Sabatés, J.; Bahar-Fuchs, A. Cognition-oriented treatments for older adults: A systematic overview of systematic reviews. Neuropsychol. Rev. 2020, 30, 167–193.
  26. Rody, T.; De Amorim, J.A.; De Felice, F.G. The emerging neuroprotective roles of exerkines in Alzheimer’s disease. Front. Aging Neurosci. 2022, 14, 965190.
  27. Yusufov, M.; Weyandt, L.L.; Piryatinsky, I. Alzheimer’s disease and diet: A systematic review. Int. J. Neurosci. 2017, 127, 161–175.
  28. Yu, J.T.; Xu, W.; Tan, C.C.; Andrieu, S.; Suckling, J.; Evangelou, E.; Pan, A.; Zhang, C.; Jia, J.; Feng, L.; et al. Evidence-based prevention of Alzheimer’s disease: Systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J. Neurol. Neurosurg. Psychiatry 2020, 91, 1201–1209.
  29. Chalfont, G.; Milligan, C.; Simpson, J. A mixed methods systematic review of multimodal non-pharmacological interventions to improve cognition for people with dementia. Dementia 2020, 19, 1086–1130.
  30. Cheng, A.; Hou, Y.; Mattson, M.P. Mitochondria and neuroplasticity. ASN Neuro 2010, 2, e00045.
  31. Robinson, A.; Grosgen, S.; Mett, J.; Zimmer, V.C.; Haupenthal, V.J.; Hundsdorfer, B.; Stahlmann, C.P.; Slobodskoy, Y.; Muller, U.C.; Hartmann, T.; et al. Upregulation of pgc-1alpha expression by Alzheimer’s disease-associated pathway: Presenilin 1/amyloid precursor protein (app)/intracellular domain of app. Aging Cell 2014, 13, 263–272.
  32. Chianese, R.; Coccurello, R.; Viggiano, A.; Scafuro, M.; Fiore, M.; Coppola, G.; Operto, F.F.; Fasano, S.; Laye, S.; Pierantoni, R.; et al. Impact of dietary fats on brain functions. Curr. Neuropharmacol. 2018, 16, 1059–1085.
  33. Wurtman, R.J.; Ulus, I.H.; Cansev, M.; Watkins, C.J.; Wang, L.; Marzloff, G. Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res. 2006, 1088, 83–92.
  34. Wurtman, R.J.; Cansev, M.; Sakamoto, T.; Ulus, I.H. Use of phosphatide precursors to promote synaptogenesis. Annu. Rev. Nutr. 2009, 29, 59–87.
  35. van Wijk, N.; Broersen, L.M.; de Wilde, M.C.; Hageman, R.J.; Groenendijk, M.; Sijben, J.W.; Kamphuis, P.J. Targeting synaptic dysfunction in Alzheimer’s disease by administering a specific nutrient combination. J. Alzheimer’s Dis. 2014, 38, 459–479.
  36. Janickova, H.; Rudajev, V.; Dolejsi, E.; Koivisto, H.; Jakubik, J.; Tanila, H.; El-Fakahany, E.E.; Dolezal, V. Lipid-based diets improve muscarinic neurotransmission in the hippocampus of transgenic appswe/ps1de9 mice. Curr. Alzheimer Res. 2015, 12, 923–931.
  37. Ali, A.A.; Abd El-Fattah, A.I.; Abu-Elfotuh, K.; Elariny, H.A. Natural antioxidants enhance the power of physical and mental activities versus risk factors inducing progression of Alzheimer’s disease in rats. Int. Immunopharmacol. 2021, 96, 107729.
  38. Ngandu, T.; Lehtisalo, J.; Solomon, A.; Levälahti, E.; Ahtiluoto, S.; Antikainen, R.; Bäckman, L.; Hänninen, T.; Jula, A.; Laatikainen, T.; et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (finger): A randomised controlled trial. Lancet 2015, 385, 2255–2263.
  39. Moll van Charante, E.P.; Richard, E.; Eurelings, L.S.; van Dalen, J.W.; Ligthart, S.A.; van Bussel, E.F.; Hoevenaar-Blom, M.P.; Vermeulen, M.; van Gool, W.A. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (prediva): A cluster-randomised controlled trial. Lancet 2016, 388, 797–805.
  40. Andrieu, S.; Guyonnet, S.; Coley, N.; Cantet, C.; Bonnefoy, M.; Bordes, S.; Bories, L.; Cufi, M.N.; Dantoine, T.; Dartigues, J.F.; et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (mapt): A randomised, placebo-controlled trial. Lancet Neurol. 2017, 16, 377–389.
  41. Salzman, T.; Sarquis-Adamson, Y.; Son, S.; Montero-Odasso, M.; Fraser, S. Associations of multidomain interventions with improvements in cognition in mild cognitive impairment: A systematic review and meta-analysis. JAMA Netw. Open 2022, 5, e226744.
  42. Sharew, N.T. The effect of multimodal non-pharmacological interventions on cognitive function improvement for people with dementia: A systematic review. Front. Public Health 2022, 10, 894930.
  43. Liu, T.; Spector, A.; Mograbi, D.C.; Cheung, G.; Wong, G.H.Y. Changes in default mode network connectivity in resting-state fmri in people with mild dementia receiving cognitive stimulation therapy. Brain Sci. 2021, 11, 1137.
  44. Stephen, R.; Ngandu, T.; Liu, Y.; Peltonen, M.; Antikainen, R.; Kemppainen, N.; Laatikainen, T.; Lötjönen, J.; Rinne, J.; Strandberg, T.; et al. Change in caide dementia risk score and neuroimaging biomarkers during a 2-year multidomain lifestyle randomized controlled trial: Results of a post-hoc subgroup analysis. J. Gerontol. Ser. A 2021, 76, 1407–1414.
  45. Stephen, R.; Liu, Y.; Ngandu, T.; Antikainen, R.; Hulkkonen, J.; Koikkalainen, J.; Kemppainen, N.; Lötjönen, J.; Levälahti, E.; Parkkola, R.; et al. Brain volumes and cortical thickness on mri in the finnish geriatric intervention study to prevent cognitive impairment and disability (finger). Alzheimer’s Res. Ther. 2019, 11, 53.
  46. Smith, P.J.; Blumenthal, J.A.; Babyak, M.A.; Craighead, L.; Welsh-Bohmer, K.A.; Browndyke, J.N.; Strauman, T.A.; Sherwood, A. Effects of the dietary approaches to stop hypertension diet, exercise, and caloric restriction on neurocognition in overweight adults with high blood pressure. Hypertension 2010, 55, 1331–1338.
  47. Han, K.; Tang, Z.; Bai, Z.; Su, W.; Zhang, H. Effects of combined cognitive and physical intervention on enhancing cognition in older adults with and without mild cognitive impairment: A systematic review and meta-analysis. Front. Aging Neurosci. 2022, 14, 878025.
  48. Collins, R.; Hunt, A.; Quinn, C.; Martyr, A.; Pentecost, C.; Clare, L. Methods and approaches for enhancing communication with people with moderate-to-severe dementia that can facilitate their inclusion in research and service evaluation: Findings from the ideal programme. Dementia 2022, 21, 1135–1153.
  49. Nguyen, H.; Terry, D.; Phan, H.; Vickers, J.; McInerney, F. Communication training and its effects on carer and care-receiver outcomes in dementia settings: A systematic review. J. Clin. Nurs. 2019, 28, 1050–1069.
  50. Lobbia, A.; Carbone, E.; Faggian, S.; Gardini, S.; Piras, F.; Spector, A.; Borella, E. The efficacy of cognitive stimulation therapy (cst) for people with mild-to-moderate dementia. Eur. Psychol. 2019, 24, 257–277.
  51. Spector, A.; Orrell, M.; Woods, B. Cognitive stimulation therapy (cst): Effects on different areas of cognitive function for people with dementia. Int. J. Geriatr. Psychiatry 2010, 25, 1253–1258.
  52. Swan, K.; Hopper, M.; Wenke, R.; Jackson, C.; Till, T.; Conway, E. Speech-language pathologist interventions for communication in moderate-severe dementia: A systematic review. Am. J. Speech-Lang. Pathol. 2018, 27, 836–852.
  53. Rogalski, E.J.; Khayum, B. A life participation approach to primary progressive aphasia intervention. Semin. Speech Lang. 2018, 39, 284–296.
  54. Bourgeois, M.S.; Hickey, E.M. Dementia: From Diagnosis to Management—A Functional Approach; Taylor & Francis: New York, NY, USA, 2009.
  55. Beales, A.; Whitworth, A.; Cartwright, J.; Panegyres, P.K.; Kane, R.T. Making the right connections: Maximizing lexical generalization in lexical impairments in primary progressive aphasia and Alzheimer’s disease. Am. J. Speech-Lang. Pathol. 2021, 30, 697–712.
  56. Capotosto, E.; Belacchi, C.; Gardini, S.; Faggian, S.; Piras, F.; Mantoan, V.; Salvalaio, E.; Pradelli, S.; Borella, E. Cognitive stimulation therapy in the italian context: Its efficacy in cognitive and non-cognitive measures in older adults with dementia. Int. J. Geriatr. Psychiatry 2017, 32, 331–340.
  57. Carbone, E.; Gardini, S.; Pastore, M.; Piras, F.; Vincenzi, M.; Borella, E. Cognitive stimulation therapy for older adults with mild-to-moderate dementia in italy: Effects on cognitive functioning, and on emotional and neuropsychiatric symptoms. J. Gerontol. Ser. B Psychol. Sci. Soc. Sci. 2021, 76, 1700–1710.
  58. Walter, E.; Pinquart, M. How effective are dementia caregiver interventions? An updated comprehensive meta-analysis. Gerontologist 2020, 60, 609–619.
  59. Vicente de Sousa, O.; Soares Guerra, R.; Sousa, A.S.; Pais Henriques, B.; Pereira Monteiro, A.; Amaral, T.F. Impact of nutritional supplementation and a psychomotor program on patients with Alzheimer’s disease. Am. J. Alzheimer’s Dis. Other Dement. 2017, 32, 329–341.
  60. He, J.; Wang, J.; Zhong, H.; Guan, C. The effectiveness of multi-component interventions on the positive and negative aspects of well-being among informal caregivers of people with dementia: A systematic review and meta-analysis. Int. J. Environ. Res. Public Health 2022, 19, 6973.
  61. Kamer, A.R.; Craig, R.G.; Pirraglia, E.; Dasanayake, A.P.; Norman, R.G.; Boylan, R.J.; Nehorayoff, A.; Glodzik, L.; Brys, M.; de Leon, M.J. Tnf-alpha and antibodies to periodontal bacteria discriminate between Alzheimer’s disease patients and normal subjects. J. Neuroimmunol. 2009, 216, 92–97.
  62. Jungbauer, G.; Stähli, A.; Zhu, X.; Auber Alberi, L.; Sculean, A.; Eick, S. Periodontal microorganisms and Alzheimer disease—A causative relationship? Periodontology 2000 2022, 89, 59–82.
  63. Noble, J.M.; Scarmeas, N.; Celenti, R.S.; Elkind, M.S.; Wright, C.B.; Schupf, N.; Papapanou, P.N. Serum igg antibody levels to periodontal microbiota are associated with incident Alzheimer disease. PLoS ONE 2014, 9, e114959.
  64. Jockusch, J.; Wiedemeier, D.; Nitschke, I. The orbid (oral health, bite force and dementia) pilot study: A study protocol for new approaches to masticatory muscle training and efficient recruitment for longitudinal studies in people with dementia. Int. J. Environ. Res. Public Health 2022, 19, 3700.
  65. Nitschke, I.; Hahnel, S. Zahnmedizinische versorgung älterer menschen: Chancen und herausforderungen. Bundesgesundheitsblatt Gesundh. Gesundh. 2021, 64, 802–811.
  66. Desta, N.T. Pathophysiological association between periodontal disease and Alzheimer’s disease: Importance of periodontal health in the elderly. J. Oral Biosci. 2021, 63, 351–359.
  67. Dioguardi, M.; Di Gioia, G.; Caloro, G.A.; Capocasale, G.; Zhurakivska, K.; Troiano, G.; Lo Russo, L.; Lo Muzio, L. The association between tooth loss and Alzheimer’s disease: A systematic review with meta-analysis of case control studies. Dent. J. 2019, 7, 49.
  68. Ahmed, S.E.; Mohan, J.; Kalaignan, P.; Kandasamy, S.; Raju, R.; Champakesan, B. Influence of dental prostheses on cognitive functioning in elderly population: A systematic review. J. Pharm. Bioallied Sci. 2021, 13, S788–S794.
  69. Harding, A.; Robinson, S.; Crean, S.; Singhrao, S.K. Can better management of periodontal disease delay the onset and progression of Alzheimer’s disease? J. Alzheimer’s Dis. 2017, 58, 337–348.
  70. Athanasaki, A.; Melanis, K.; Tsantzali, I.; Stefanou, M.I.; Ntymenou, S.; Paraskevas, S.G.; Kalamatianos, T.; Boutati, E.; Lambadiari, V.; Voumvourakis, K.I.; et al. Type 2 diabetes mellitus as a risk factor for Alzheimer’s disease: Review and meta-analysis. Biomedicines 2022, 10, 778.
  71. Janoutova, J.; Machaczka, O.; Zatloukalova, A.; Janout, V. Is Alzheimer’s disease a type 3 diabetes? A review. Cent. Eur. J. Public Health 2022, 30, 139–143.
  72. Stohr, J.; Barbaresko, J.; Neuenschwander, M.; Schlesinger, S. Bidirectional association between periodontal disease and diabetes mellitus: A systematic review and meta-analysis of cohort studies. Sci. Rep. 2021, 11, 13686.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Others
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Irene Ablinger
,
Katharina Dressel
,
Anna Andrea Lauer
,
Heike Sabine Grimm
,
Marcus Otto Walter Grimm
View Times: 886
Revisions: 3 times (View History)
Update Date: 21 Dec 2022
Table of Contents
Academic Video Service
Feedback